Overview

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of amifostine in treating patients who have stage II or stage III non-small cell lung cancer that cannot be surgically removed and who are undergoing chemotherapy and radiation therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Radiation Therapy Oncology Group
Collaborators:
National Cancer Institute (NCI)
NRG Oncology
Treatments:
Albumin-Bound Paclitaxel
Amifostine
Carboplatin
Paclitaxel